Biosynex Stock

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris 11:55:00 2026-09-25 am EDT			5-day change	1st Jan Change
0.9300 ^EUR	+4.03%		+3.33%	+56.04%

Sep. 04	Biosynex: creditors to vote on financial safeguard plan
Aug. 06	Biosynex hit by cyberattack, operational activity remains intact

News in other languages: Biosynex

Sep. 25	BIOSYNEX SA: Vote favorable d’une large majorité des classes de parties affectées en faveur du projet de plan de sauvegarde de la Société BIOSYNEX
Sep. 21	Les derniers choix des stars de la gestion : un bel été, mais une rentrée compliquée
Sep. 04	Biosynex : vote des créanciers sur le plan de sauvegarde financière
Sep. 04	BIOSYNEX SA: Notification des créanciers de Biosynex réunis en classes de parties affectées pour voter sur le projet de plan de sauvegarde - Principaux termes du projet de plan de sauvegarde
Sep. 01	Biosynex : Thierry Paper quitte ses fonctions avec effet immédiat

More news

Managers and Directors: Biosynex

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

More insiders

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	+4.03%	+3.33%	-23.14%	-90.65%	19.53M
GUARDANT HEALTH, INC.	+0.45%	-1.19%	+194.53%	+574.98%	23.79B
10X GENOMICS, INC.	+1.90%	+11.89%	+617.24%	+107.98%	11.17B
BIOMÉRIEUX	+0.71%	+8.52%	-30.62%	-14.26%	10.42B
CARIS LIFE SCIENCES, INC.	-0.90%	+6.67%	+7.57%	-	9.04B
LANTHEUS HOLDINGS, INC.	+0.02%	-0.81%	+93.78%	+54.35%	6.51B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-2.43%	-2.47%	-30.22%	-24.83%	5.59B
DIASORIN S.P.A.	+0.33%	+2.85%	+6.23%	-8.37%	4.45B
ANDON HEALTH CO., LTD.	-2.61%	-0.71%	+58.81%	+63.00%	3.86B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.29%	+4.60%	-15.00%	-27.63%	2.86B
Average	-0.08%	+3.27%	+87.92%	+70.51%	7.77B
Weighted average by Cap.	+0.03%	+3.32%	+153.45%	+219.56%

See all sector performances

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-09-25	€0.9300	+4.03%	149,152
26-09-24	€0.8940	-1.54%	23,694
26-09-23	€0.9080	-1.52%	3,244
26-09-22	€0.9220	+2.90%	35,905
26-09-21	€0.8960	-0.44%	1,530

Real-time Euronext Paris

More quotes

Market Cap	17.14M 19.53M 16.19M 14.75M 27.62M 1.87B 27.82M 194M 75.04M 957M 73.34M 71.76M 3.07B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	70.33M 80.15M 66.43M 60.53M 113M 7.68B 114M 795M 308M 3.92B 301M 294M 12.61B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALBIO	Real-time
Deutsche Boerse AG	0DL	Delayed
Börse Stuttgart	0DL	Delayed
Boerse Muenchen	0DL	Real-time
CBOE		Real-time
CBOE		Real-time

Sep. 04	Biosynex: creditors to vote on financial safeguard plan
Aug. 06	Biosynex hit by cyberattack, operational activity remains intact
Jun. 11	Triple update for Biosynex
Jun. 10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
May. 25	Paris climbs on hopes of Middle East de-escalation
May. 25	Biosynex announces the divestment of its molecular biology business
May. 24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
May. 07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
Apr. 21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
Apr. 21	Biosynex postpones publication of annual accounts
Mar. 24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
Mar. 24	Observation period extended for Biosynex

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

1 day	+4.03%
1 week	+3.33%
Current month	+3.56%
1 month	+3.10%
3 months	+4.03%
6 months	+11.78%
Current year	+56.04%

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news: Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Price Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	0.89	1.06
1 month	0.81	1.06
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	10.18
5 years	0.46	28.78
10 years	0.46	30.38

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/28/22	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

	2024	2025
Net sales	101M 115M 95.55M 87.07M 163M 11.05B 164M 1.14B 443M 5.65B 433M 424M 18.14B	95.19M 108M 89.91M 81.93M 153M 10.4B 154M 1.08B 417M 5.31B 407M 399M 17.07B
Net income	-43.33M -49.38M -40.93M -37.3M -69.82M -4.73B -70.31M -490M -190M -2.42B -185M -181M -7.77B	-58.22M -66.35M -54.99M -50.11M -93.81M -6.36B -94.48M -658M -255M -3.25B -249M -244M -10.44B
Net Debt	52.94M 60.33M 50M 45.56M 85.29M 5.78B 85.9M 598M 232M 2.95B 226M 222M 9.49B	53.19M 60.62M 50.24M 45.78M 85.7M 5.81B 86.31M 601M 233M 2.97B 228M 223M 9.54B